Firmagon(degarelix)
Degarelix, Firmagon (degarelix) is a protein pharmaceutical. Degarelix was first approved as Firmagon on 2008-12-24. It is used to treat prostatic neoplasms in the USA. It has been approved in Europe to treat prostatic neoplasms. The pharmaceutical is active against gonadotropin-releasing hormone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Firmagon
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Degarelix acetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FIRMAGON | Ferring Pharmaceuticals | N-022201 RX | 2008-12-24 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| firmagon | New Drug Application | 2024-01-30 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| prostatic neoplasms | — | D011471 | C61 |
Agency Specific
FDA
EMA
No data
HCPCS
Code | Description |
|---|---|
| J9155 | Injection, degarelix, 1 mg |
Clinical
Clinical Trials
157 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 17 | 60 | 35 | 6 | 26 | 131 |
| Menopause | D008593 | EFO_0003922 | N95 | — | — | — | 3 | 1 | 4 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | — | 1 | 2 | 1 | — | 4 |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | 3 | — | 3 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | — | 2 | — | 1 | — | 3 |
| Hyperplasia | D006965 | EFO_0000536 | — | — | 2 | — | 1 | — | 3 |
| Abdominal obesity | D056128 | HP_0001956 | — | — | — | — | 1 | — | 1 |
| Weight gain | D015430 | HP_0004324 | — | — | — | — | 1 | — | 1 |
| Adiposity | D050154 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | D000230 | — | — | 1 | 10 | 5 | — | 2 | 17 |
| Carcinoma | D002277 | — | C80.0 | 1 | 2 | 1 | — | 1 | 5 |
| Infertility | D007246 | HP_0000789 | — | — | 1 | 1 | — | 2 | 4 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 2 | 1 | 1 | — | — | 4 |
| Recurrence | D012008 | — | — | — | 1 | 1 | — | — | 2 |
| Neoplasms | D009369 | — | C80 | — | — | 1 | — | — | 1 |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | — | — | 1 | — | — | 1 |
| Ovarian pregnancy | D065172 | — | O00.2 | — | — | 1 | — | — | 1 |
| Endometriosis | D004715 | EFO_0001065 | N80 | — | — | 1 | — | — | 1 |
| Anemia | D000740 | HP_0001903 | D64.9 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypersensitivity | D006967 | HP_0012393 | T78.40 | 1 | 5 | — | — | 1 | 7 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 3 | — | — | — | 3 |
| Female infertility | D007247 | EFO_0008560 | N97 | — | 1 | — | — | 1 | 2 |
| Neoadjuvant therapy | D020360 | — | — | — | 1 | — | — | — | 1 |
| Prostatectomy | D011468 | — | — | — | 1 | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 1 | — | — | — | 1 |
| Ductal carcinoma breast | D018270 | — | — | — | 1 | — | — | — | 1 |
| Covid-19 | D000086382 | — | — | — | 1 | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | — | 1 | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | 1 | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | — | — | — | — | 1 | 1 |
| Premature menopause | D008594 | HP_0008209 | E28.31 | — | — | — | — | 1 | 1 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 1 | 1 |
| Fertility | D005298 | — | — | — | — | — | — | 1 | 1 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | — | 1 | 1 |
| Vascular stiffness | D059289 | — | — | — | — | — | — | 1 | 1 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | — | — | — | 1 | 1 |
| Fertilization in vitro | D005307 | — | — | — | — | — | — | 1 | 1 |
| Ovarian hyperstimulation syndrome | D016471 | — | — | — | — | — | — | 1 | 1 |
| Syndrome | D013577 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Degarelix |
| INN | degarelix |
| Description | Degarelix is a polypeptide. |
| Classification | Protein |
| Drug class | hormone-release inhibiting peptides |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O |
Identifiers
| PDB | — |
| CAS-ID | 214766-78-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL415606 |
| ChEBI ID | — |
| PubChem CID | 16136245 |
| DrugBank | DB06699 |
| UNII ID | SX0XJI3A11 (ChemIDplus, GSRS) |
Target
Agency Approved
GNRHR
GNRHR
Organism
Homo sapiens
Gene name
GNRHR
Gene synonyms
GRHR
NCBI Gene ID
Protein name
gonadotropin-releasing hormone receptor
Protein synonyms
gnRH receptor, gnRH-R, gonadotropin-releasing hormone (type 1) receptor 1, leutinizing hormone releasing horomone receptor, leutinizing-releasing hormone receptor, luliberin receptor, type I GnRH receptor
Uniprot ID
Mouse ortholog
Gnrhr (14715)
gonadotropin-releasing hormone receptor (Q61611)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,322 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,087 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use